Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kobayashi Pharma to Revamp Management under New President
January 22, 2025
- Daito Bags Approval for Pain Medicine Pregabalin in China
January 22, 2025
- Lilly/Mitsubishi Tanabe to Push Proper Use of Zepbound
January 21, 2025
- Mitsubishi Chemical Says It’s Exploring All Options for Portfolio Reform
January 21, 2025
- Japanese PI Waiver Good News to Mega Pharma and Emerging Players Alike: Pfizer Execs
January 21, 2025
- Sumitomo, Janssen Tie Up for Xeplion Sales in Japan
January 21, 2025
- FDA Approves Daiichi’s New ADC Datroway for Breast Cancer
January 21, 2025
- Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
January 20, 2025
- Cell and Gene Therapy Market Expected to Top US$20 Billion by 2028: IQVIA
January 20, 2025
- Shionogi Reels in US$375 Million HHS Funding for Preventive COVID-19 Med
January 20, 2025
- Senju Files Mochida-Partnered Dry Eye Drug in Japan
January 20, 2025
- Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
- Astellas to Offload Seroquel, “G1” LLP, to LTL Pharma
January 17, 2025
- J-TEC, Kobe Cell Therapy Player Form Capital Alliance
January 16, 2025
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- AnGes Partners with Stanford on Cancer Therapy Research
January 16, 2025
- Mochida to File Actemra Biosimilar in Japan
January 16, 2025
- ASKA/Veneno Tie Up for Discovery of Ion Channel Therapies
January 15, 2025
- Kyorin, Biodol Ink Option Deal for Novel Pain Drug
January 15, 2025
- Nippon Shinyaku Grabs Rights to Regenxbio’s MPS Gene Therapies
January 15, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…